Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunomodulation by intravenous gamma globulin?].

V Wahn

    Immunitat Und Infektion
    |February 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    High-dose intravenous immunoglobulin therapy offers new therapeutic uses beyond antibody replacement. It shows potential for modulating abnormal immune responses, with ongoing research exploring its clinical applications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Positive Kappa-Deleting Recombination Excision Circles (KREC) Newborn Screening in a Neonate With Intrauterine Exposure to Rituximab.

    Scandinavian journal of immunology·2017
    Same author

    [Interdisciplinary AWMF guideline for the treatment of primary antibody deficiencies].

    Klinische Padiatrie·2012
    Same author

    [Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2012
    Same author

    Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies.

    European journal of pediatrics·2012
    Same author

    Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

    Clinical immunology (Orlando, Fla.)·2011
    Same author

    Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).

    Klinische Padiatrie·2011

    Area of Science:

    • Immunology
    • Pharmacology
    • Therapeutics

    Background:

    • Intravenous immunoglobulin (IVIG) preparations have continuously improved.
    • New therapeutic applications are emerging beyond antibody deficiency.
    • High-dose IVIG may influence immune system functions.

    Purpose of the Study:

    • To discuss the theoretical basis for new IVIG applications.
    • To review clinical evidence supporting these new uses.
    • To explore the immunomodulatory effects of high-dose IVIG.

    Main Methods:

    • Review of theoretical frameworks for IVIG immunomodulation.
    • Analysis of clinical data from studies using high-dose IVIG.
    • Discussion of pathological immune alterations targeted by IVIG.

    Related Experiment Videos

    Main Results:

    • IVIG's therapeutic potential extends beyond antibody substitution.
    • High-dose administration may positively impact immune dysregulation.
    • Clinical evidence supports IVIG's role in managing altered immune functions.

    Conclusions:

    • Continuous advancements in IVIG manufacturing enable novel therapeutic strategies.
    • High-dose IVIG represents a promising approach for immune modulation.
    • Further research and clinical application are warranted for these expanded uses.